Drugs / stannsoporfin

Trials 11 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00004397 Jan 1998 → May 2000 porphyria National Center for Research Resources (NCRR) Completed No outcome recorded
Phase 1 NCT00004398 Jan 1998 → May 2000 porphyria National Center for Research Resources (NCRR) Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00004789 Jul 1993 → ? porphyria National Center for Research Resources (NCRR) Completed No outcome recorded
Phase 26 trials
Phase 2 NCT01887327 Oct 2013 → Mar 2016 hyperbilirubinemia InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company Completed No outcome recorded
Phase 2 NCT00850993 Aug 2008 → Jun 2011 hyperbilirubinemia InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company Terminated No outcome recorded
Phase 2 NCT00115544 Sep 2005 → Jul 2006 hyperbilirubinemia InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company Completed No outcome recorded
Phase 2 NCT00004381 Dec 1999 → ? G6PD deficiency, blood group incompatibility, hyperbilirubinemia Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed No outcome recorded
Phase 2 NCT00004382 Dec 1999 → Aug 2007 hyperbilirubinemia Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed No outcome recorded
Phase 2 NCT00004396 Sep 1997 → ? porphyria National Center for Research Resources (NCRR) Completed No outcome recorded
Phase 31 trial
Phase 3 NCT02685137 May 2002 → Mar 2003 metabolic disease InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company Completed No outcome recorded
Phase not stated1 trial
NCT00076960 congenital nonhemolytic jaundice, hyperbilirubinemia InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company No longer available No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as stannsoporfin “The purpose of this study is to evaluate the effect and safety of Stanate (stannsoporfin) in infants who are at risk for an exchange transfusion and meet the criteria of the protocol.” NCT00115544
4

NCT02685137

NCT00850993

NCT00076960

NCT01887327

Known as B-992 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297207
Known as Estansoporfina ChEMBL registry synonym — accepted as the source's own label CHEMBL4297207
Known as Mesoporphyrin tin ChEMBL registry synonym — accepted as the source's own label CHEMBL4297207
Known as Stanate “The purpose of this study is to evaluate the effect and safety of Stanate (stannsoporfin) in infants who are at risk for an exchange transfusion and meet the criteria of the protocol.” NCT00115544
Known as Stanate (TM) Stanate (TM) [stannsoporfin, tin-mesoporphyrin]” NCT00076960
Known as Stannsoporfine ChEMBL registry synonym — accepted as the source's own label CHEMBL4297207
Known as tin-mesoporphyrin “Stanate (TM) [stannsoporfin, tin-mesoporphyrin]” NCT00076960
6

NCT00004789

NCT00004382

NCT00004381

NCT00004396

NCT00004398

NCT00004397

Modality Small molecule CHEMBL4297207
Route Intravenous “Patients receive tin mesoporphyrin IV as a single dose.” NCT00004396